Anti-tumor preparation and preparation method thereof

Abstract

The invention belongs to the technical field of medicine, and discloses an anti-tumor preparation and a preparation method thereof, wherein the anti-tumor preparation is stem cells loading an anti-PD-L1 / PD-1 humanized antibody. The preparation method comprises: linking the fragment into a commercial lentivirus or adenovirus expression vector through restriction endonuclease and ligase; packaging target viruses containing an anti-PD-L1 / PD-1 humanized gene by culturing 293T cells, and detecting the titer; infecting amnion stem cells with the viruses; and obtaining a cell line stably expressing the anti-PD-L1 / PD-1 humanized antibody by selecting a monoclone, detecting the insertion position of the target gene through sequencing, detecting the expression position of the target protein, and expressing the target protein on the cell membrane. According to the present invention, the anti-PD-L1 / PD-1 humanized antibody can be targeted to tumor tissues by stem cells so as to reduce the side effects caused by systemic administration.

Description

Technical field [0001] The invention belongs to the technical field of medicine, and particularly relates to an anti-tumor preparation and a preparation method. Background technique [0002] At present, the existing technology commonly used in the industry is as follows: [0003] Broad-spectrum anti-tumor therapy based on immune checkpoints is a breakthrough in the development and basic analysis of modern anti-tumor drugs, and was rated as a historic breakthrough in anti-tumor analysis by Science. In the tumor microenvironment, although immune cells can infiltrate tumor tissues, tumor cells can bind to PD-1 on the surface of immune cell membranes through high expression of PD-L1 on the cell surface, thereby inhibiting immune cells from exerting tumor killing effects. To achieve the purpose of immune escape. In recent years, analyses have prepared PD-L1 / PD-1 specific antibodies to block the binding of PD-L1 to PD-1 in vivo, avoiding immune tolerance induced by tumor cells, and ben...

AI Technical Summary

Problems solved by technology

[0005] (1) The existing anti-PD-1 / PD-L1 products are mainly small molecule compounds or humanized monoclonal antibodies, but the above-mentioned drugs do not have tumor targeting properties, and the drugs are distributed throughout the body after administration, so Serious side effects, including iatrogenic diabetes, severe fatal myocarditis, and other immune disorders

[0006] (2) Monoclonal antibody therapy is expensive and the treatment cycle is long, which partially limits the wide application of immune checkpoint anti-tumor therapy

[0007] (3) The existing anti-PD-1 / PD-L1 products are not effective for all patients, and the clinical effectiveness of unselected patients is only 20%, even after screening, only 60% of patients can benefit from it , which may be related to the non-concentration of drug concentration

But the existing technology is difficult to solve

Images